论文部分内容阅读
Hepatitis B virus(HBV) is a significant global pathogen and efficient cure for HBV patients is still a challenging goal. We previously reported that acidic mucopolysaccharide from stichopus japonicus selenka(SJAMP) could inhibit HBs Ag and HBe Ag expression in vitro. However, the potential anti-HBV effects of SJAMP in vivo have not yet been explored. In this study, we show that SJAMP exhibits potent anti-HBV activity in HBV transgenic mice in a dose-dependent manner. Specifically, sixty HBV transgenic male BALB/c mice were randomly selected to receive the treatment of PBS, low dose SJAMP(30 mg kg~(-1)), middle dose SJAMP(40 mg kg~(-1)), high dose SJAMP(50 mg kg~(-1)) and IFN(45 IU kg~(-1)) for 30 d. SJAMP treatment suppressed serum HBV-DNA, and liver HBs Ag and HBc Ag levels in HBV-transgenic mice. The present study highlights the potential application of SJAMP in HBV therapy.
We previously reported that acidic mucopolysaccharide from stichopus japonicus selenka (SJAMP) could inhibit HBs Ag and HBe Ag expression in vitro. However, the potential anti-HBV effects of SJAMP in vivo have not yet been explored. In this study, we show that SJAMP exhibits potent anti-HBV activity in HBV transgenic mice in a dose- dependent manner. Specifically, sixty HBV transgenic male BALB / c mice were randomly selected to receive the treatment of PBS, low dose SJAMP (30 mg kg -1), middle dose SJAMP (40 mg kg -1), high dose SJAMP (50 mg kg -1) ) and IFN (45 IU kg -1) for 30 d. SJAMP treatment suppressed serum HBV-DNA, and liver HBs Ag and HBc Ag levels in HBV-transgenic mice. The present study highlights the potential application of SJAMP in HBV therapy.